CellCarta and Waters Formed Companion Diagnostics Alliance
The partnership standardizes flow cytometry workflows across global clinical trials through Phase III testing.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you trust that deeper corporate collaboration in drug development will improve patient outcomes?
CellCarta and Waters Corporation have formed a strategic partnership to combine flow cytometry instrumentation with biomarker laboratory services. The collaboration provides biopharmaceutical sponsors with standardized testing platforms across Phase I to Phase III clinical trials.
Why it matters
By integrating standardized hardware with clinical regulatory expertise, the partnership aims to reduce complexity in global trials. This collaboration specifically enables firms to incorporate Jining, China-based testing into broader, multinational biomarker research programs.
The partnership leverages Waters' flow cytometry platforms—specialized instruments that count and sort cells—against the prior model of disparate vendor requirements. This integration allows assays developed on standardized panels to run seamlessly across CellCarta's global lab network.
The players
CellCarta
A contract research organization specializing in precision medicine, biomarker services, and regulatory-compliant laboratory testing.
Waters Corporation
A manufacturer of analytical laboratory instruments, software, and consumable products used in life sciences and clinical research.
The details
Waters contributes proprietary instrumentation, reagents, and software analysis tools to ensure data consistency across sites. CellCarta then deploys these assays within its CAP-accredited lab facilities, including its site in Jining, China, to generate regulatory-grade clinical evidence. By aligning the technical platform and the laboratory services, the companies provide a unified pipeline for biomarker validation.
Timeline
October 13, 2026: Announcement of the strategic partnership.
The Tech Race
This partnership mirrors the industry-wide move toward end-to-end integration in precision medicine to minimize site-to-site variability. It follows the pattern set by other major laboratory networks that aim to provide turnkey clinical evidence for complex multinational biomarker programs.
Biopharmaceutical sponsors can now utilize this unified platform to simplify the logistics of Phase I through Phase III trials. The partnership significantly lowers the barrier for integrating high-throughput, standardized flow cytometry data from China into global regulatory filings.
The takeaway
The alliance effectively bridges the gap between hardware manufacturers and clinical laboratory operators to streamline global diagnostics. Watch for the first multi-regional clinical trial data releases to confirm whether this integration successfully lowers program overhead.
Further reading
Learn more about the latest innovations in Biotech research and clinical testing standards.
Source note: This article includes information reported by Selectscience.
Live Poll
Do you trust that deeper corporate collaboration in drug development will improve patient outcomes?
